Will the FDA approve Viatris's fast-acting meloxicam for moderate-to-severe acute pain by January 10, 2027?
deadline 2027-01-10
confidence medium
tier 4 evidence
79%Asturna estimate
⚠ Evidence cap applied: the model proposed 78%, brought back to 79% for lack of sources solid enough to justify the departure from the base rate.
Resolution criterion
Yes if the FDA approves fast-acting meloxicam for the indication stated above (Drugs@FDA entry, FDA announcement or Viatris press release) no later than January 10, 2027. A complete response letter, an extension of the PDUFA date or the absence of a decision by then counts as no. An accelerated or conditional approval counts as an approval; a later label update does not change the outcome.
Verified starting state
As of October 25, 2026: according to the Viatris filing of August 6, 2026, the FDA has set a PDUFA target action date of December 27, 2026. Source: https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/exhibit991-2q26earningsrel.htm
What pushes it up
- PDUFA target action date of December 27, 2026 indicates FDA plans to decide before the deadline [tier 1]
- FDA acceptance of the NDA in May 2026 shows the application is progressing through review stages [tier 4]
- High first‑cycle approval rate for new molecular entities (87%) supports a favorable outcome [tier 1]
What pushes it down
- No actual approval has been announced; only NDA acceptance has been reported
- PDUFA target dates are not guarantees and approvals can be delayed beyond the target
- The drug is a new non‑opioid pain therapy, a category that has faced regulatory scrutiny in the past
What would move this number most
Whether FDA will actually approve the drug by the PDUFA target date of December 27, 2026
How this number is built
| Deadline | 2027-01-10 |
| Base rate | 87% |
| Best evidence | tier 4 · 2 article(s) used |
| Independent runs | 79 · 79 · 92 (spread 13 pts) |
| Confidence | medium |
| Evidence cap | applied: 78% brought back to 79% |
| Last revised | 2026-10-25 12:16 |
| Model | openai/gpt-oss-20b (Groq) |
Sources consulted